Annette Jappe

1.3k total citations · 1 hit paper
14 papers, 1.1k citations indexed

About

Annette Jappe is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Annette Jappe has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Annette Jappe's work include PI3K/AKT/mTOR signaling in cancer (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Renal Transplantation Outcomes and Treatments (3 papers). Annette Jappe is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Renal Transplantation Outcomes and Treatments (3 papers). Annette Jappe collaborates with scholars based in Switzerland, United States and France. Annette Jappe's co-authors include Nathalie Cretin, Š Vı́tko, Bruno Daniele, Arndt Vogel, Markus Peck‐Radosavljevic, Ho Yeong Lim, Stéphane Cattan, Oezlem Anak, Andrew X. Zhu and Li‐Tzong Chen and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Annette Jappe

14 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

2014 449 citations Andrew X. Zhu, Masatoshi Kudo et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annette Jappe Switzerland	11	354	314	280	242	241	14	1.1k
Kengo Fukuzawa Japan	20	366 1.0×	24 0.1×	536 1.9×	286 1.2×	86 0.4×	66	1.1k
Juan Sanabria United States	15	406 1.1×	36 0.1×	506 1.8×	225 0.9×	65 0.3×	35	885
Akihisa Nagatsu Japan	12	324 0.9×	138 0.4×	423 1.5×	107 0.4×	79 0.3×	60	880
Shinichi Nakanuma Japan	18	116 0.3×	16 0.1×	202 0.7×	122 0.5×	173 0.7×	93	752
Kenya Yamanaka Japan	17	319 0.9×	12 0.0×	327 1.2×	134 0.6×	133 0.6×	42	711
Kiyohiko Dohi Japan	14	132 0.4×	17 0.1×	195 0.7×	257 1.1×	183 0.8×	43	751
Clare Pattenden United Kingdom	14	115 0.3×	15 0.0×	405 1.4×	155 0.6×	162 0.7×	21	902
Francis Navarro France	17	246 0.7×	10 0.0×	388 1.4×	192 0.8×	86 0.4×	43	773
Claire Goumard France	21	893 2.5×	15 0.0×	679 2.4×	281 1.2×	66 0.3×	85	1.3k
Toshiro Ogata Japan	16	99 0.3×	27 0.1×	216 0.8×	158 0.7×	114 0.5×	61	579

Countries citing papers authored by Annette Jappe

Since Specialization

Citations

This map shows the geographic impact of Annette Jappe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annette Jappe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annette Jappe more than expected).

Fields of papers citing papers by Annette Jappe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annette Jappe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annette Jappe. The network helps show where Annette Jappe may publish in the future.

Co-authorship network of co-authors of Annette Jappe

This figure shows the co-authorship network connecting the top 25 collaborators of Annette Jappe. A scholar is included among the top collaborators of Annette Jappe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annette Jappe. Annette Jappe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Zhang, L., Yuankai Shi, Daniel S.W. Tan, et al.. (2016). 445PD ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK- rearranged (ALK +) non-small cell lung cancer (NSCLC) previously treated with crizotinib. Annals of Oncology. 27. ix143–ix143. 3 indexed citations

Isaacs, Claudine, Ruth O’Regan, Binghe Xu, et al.. (2016). Abstract P4-13-12: Everolimus plus trastuzumab and vinorelbine for trastuzumab-resistant, taxane-pretreated, HER2+ advanced breast cancer: Overall survival results from BOLERO-3. Cancer Research. 76(4_Supplement). P4–13. 2 indexed citations

Zhu, Andrew X., Masatoshi Kudo, Eric Assénat, et al.. (2014). EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.. Journal of Clinical Oncology. 32(3_suppl). 172–172. 33 indexed citations

Zhu, Andrew X., Masatoshi Kudo, Eric Assénat, et al.. (2014). Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib. JAMA. 312(1). 57–57. 449 indexed citations breakdown →

Guo, Jun, Yong Huang, Xu Zhang, et al.. (2013). Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study. BMC Cancer. 13(1). 136–136. 24 indexed citations

Urva, Shweta, et al.. (2013). A Phase I Study Evaluating the Effect of Everolimus on the Pharmacokinetics of Midazolam in Healthy Subjects. The Journal of Clinical Pharmacology. 53(4). 444–450. 13 indexed citations

Papadimitrakopoulou, Vassiliki A., Jean‐Charles Soria, Annette Jappe, et al.. (2012). Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 7(10). 1594–1601. 28 indexed citations

Xu, Binghe, Yi‐Long Wu, Lin Shen, et al.. (2011). Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. Journal of Hematology & Oncology. 4(1). 3–3. 26 indexed citations

Cheung, Wing K., et al.. (2011). Pharmacokinetic (PK) profile of a single dose of everolimus (10 mg) administered with a low- or high-fat meal and under fasting conditions in healthy subjects.. Journal of Clinical Oncology. 29(15_suppl). e15080–e15080. 6 indexed citations

10.

Schöffski, Patrick, Peter Reichardt, Jean‐Yves Blay, et al.. (2010). A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Annals of Oncology. 21(10). 1990–1998. 102 indexed citations

11.

Leighl, N. B., Jean‐Charles Soria, Jaafar Bennouna, et al.. (2010). Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 7524–7524. 15 indexed citations

12.

Dumez, Herlinde, Jean‐Yves Blay, Patrick Schöffski, et al.. (2008). A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology. 26(15_suppl). 10519–10519. 14 indexed citations

13.

Vı́tko, Š, Hélio Tedesco‐Silva, Josette Eris, et al.. (2004). Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies. American Journal of Transplantation. 4(4). 626–635. 207 indexed citations

14.

Vı́tko, Š, Raimund Margreiter, Willem Weimar, et al.. (2004). Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients. Transplantation. 78(10). 1532–1540. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact